
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
Results from the ASPEN trial also show that brensocatib displayed several benefits when used in patients with bronchiectasis, including a reduction in symptom burden.






















